Brainsway’s Market Expansion and Strong Revenue Performance Justify Buy Rating

Tip Ranks
2025.11.13 15:45
portai
I'm PortAI, I can summarize articles.

Analyst Ram Selvaraju of H.C. Wainwright reiterated a Buy rating on Brainsway, raising the price target to $18.00. The rating is based on Brainsway's FDA label expansion for its Deep TMS system, strong 3Q25 revenue performance, and strategic growth initiatives. Despite a modest bottom-line miss, the company's financial health and significant cash reserve support the positive outlook. Ladenburg Thalmann & Co. also reiterated a Buy rating with a $19.00 price target.

Analyst Ram Selvaraju of H.C. Wainwright reiterated a Buy rating on Brainsway, boosting the price target to $18.00.

Meet Your ETF AI Analyst

  • Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
  • Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.

Ram Selvaraju has given his Buy rating due to a combination of factors, including Brainsway’s recent FDA label expansion for its Deep TMS system. This expansion allows the system to be used as an adjunct therapy for adolescents with major depressive disorder, broadening its market potential. Additionally, the company has shown a strong revenue performance with a 29% increase in 3Q25, surpassing expectations.
Furthermore, Brainsway’s strategic approach, including multi-year lease agreements and minority equity investments, provides a solid foundation for future growth. The company’s increased performance obligations and a growing installed base of Deep TMS systems contribute to a positive outlook. Despite a modest bottom-line miss, the overall financial health, including a significant cash reserve, supports the Buy rating.

Selvaraju covers the Healthcare sector, focusing on stocks such as Bioxcel Therapeutics, Emergent Biosolutions, and Genmab. According to TipRanks, Selvaraju has an average return of 23.3% and a 51.40% success rate on recommended stocks.

In another report released yesterday, Ladenburg Thalmann & Co. also reiterated a Buy rating on the stock with a $19.00 price target.

Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer